We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Amedeo
Minichino
amedeo.minichino@psych.ox.ac.uk
Amedeo
Minichino
amedeo.minichino@psych.ox.ac.uk
Schizophrenia, schizotypal and delusional disorders
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
This study (“Gut-immune Psychosis”) aims to find out whether certain immune reactions to foods—specifically antibodies against gluten—can help predict how well people diagnosed with psychosis respond to medications.
We will invite adults aged 16–55 who are having their first episode of psychosis,plus a group of healthy volunteers for comparison. Everyone will send in a stool (poo) sample and (optional) give a small blood sample. We’ll rate response to medications by measuring severity of symptoms using a standard questionnaire (PANSS) at the start and again after about 6–12 weeks of usual treatment.
By comparing people who do and don’t have these anti-gluten antibodies,we hope to see whether this “gut-immune signature” predicts who benefits most from antipsychotic treatment,and whether it’s linked to side effects like changes in weight or metabolism. If we can identify a subgroup of patients with these immune differences,it may lead to more personalised treatments—such as dietary changes or immune-targeted therapies—to improve outcomes for people with early psychosis.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Observational type: Cohort study;
You can take part if:
You may not be able to take part if:
Patients with psychosis: Serious or unstable general medical condition Learning disability or lack of fluency in English Psychotic symptoms solely attributable to substance abuse Antibiotic use within the past 3 months Night-shift work Travel across ≥2 time-zones within the 2 weeks before the baseline assessment
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
The study is sponsored by University of Oxford and funded by Wellcome Trust .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 68900
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
